Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TFX2
- Development stage
- Preclinical
- Modality
- Peptides
01
Overview
TFX2 is a selective, ribosomally-synthesized, post-translationally modified peptide antibiotic. It is produced by the bacterium Rhizobium leguminosarum bv. trifolii T24 and is one of two geometric isomers of Trifolitoxin (TFX). TFX2 exhibits potent biological activity, specifically inhibiting the growth of α-proteobacteria, including plant symbiont Rhizobium spp., plant pathogen Agrobacterium spp., and animal pathogen Brucella abortus. Its activity is significantly higher than that of its isomer, TFX1, and relies on specific amino acid residues (arginine, glutamine, glycine, and cysteine) and extensive post-translational modifications of its precursor peptide.
Beyond the preview
Go deeper on TFX2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TFX2.